Arthritis

Updated 23 November 2015

Rheumatoid arthritis can be costly

Workers with rheumatoid arthritis have higher health care and other costs for US employers than workers without the condition, a new study finds.

0

Rheumatoid arthritis is an auto-immune disease that causes pain, swelling, stiffness and loss of function in the joints, and can also affect other body organs.

How the study was done

Researchers analysed an insurance-claims database to compare the costs to employers for more than 2 700 workers with rheumatoid arthritis and more than 338 000 workers without the condition. Their study included direct health care costs and indirect costs such as missed work days.

The study found that the average yearly cost for a worker with rheumatoid arthritis was $8 700, compared with $3 500 for a worker without the condition. Direct health care costs accounted for 90% of the extra $5 200 in the total yearly costs for a worker with arthritis, according to a journal news release.

The researchers also found that workers with rheumatoid arthritis averaged about three and a half more days of health-related work absences a year than those without arthritis.

This included more sick days and more short-term disability time.

Strategies needed

Based on their findings, the researchers calculated that workers with rheumatoid arthritis cost employers nationwide an additional $5 8 billion a year, compared to workers without it. Of that total, $5 2 billion is for direct health care costs.

Workers with the condition also account for 4 million more lost work days per year than those without rheumatoid arthritis.

The study may underestimate the cost impact of rheumatoid arthritis for employers, particularly in reduced productivity, the researchers said.

"The data emphasise the need for effective management strategies that can reduce the burden of illness and economic losses incurred," concluded study co-author Richard Brook, of the JestaRx Group, which provides medical marketing services for clients in the pharmaceutical industry.

JestaRx has received funding from Abbott Laboratories. Two other study authors are employed by and own stock in Abbott, which makes drugs to treat rheumatoid arthritis, the study disclosed.

More information

The American Academy of Family Physicians has more about rheumatoid arthritis.

Read more:

Treatment of rheumatoid arthritis

Smoking associated with rheumatoid arthritis

Copyright © 2016 HealthDay. All rights reserved.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Arthritis expert

Professor Asgar Ali Kalla completed his MBChB (Bachelor of Medicine and Bachelor of Surgery) degree in 1975 at the University of Cape Town and his FRCP in 2003 in London. Professor Ali Kalla is the Isaac Albow Chair of Rheumatology at the University of Cape Town and also the Head of Division of Rheumatology at Groote Schuur Hospital. He has participated in a number of clinical trials for rheumatology and is active in community outreach. Prof Ali Kalla is an expert in Arthritis for Health24.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules